Literature DB >> 15805258

Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets.

Mitsuko Furuya1, Hiroaki Kato, Norihiro Nishimura, Isamu Ishiwata, Hitoshi Ikeda, Ryoko Ito, Takashi Yoshiki, Hiroshi Ishikura.   

Abstract

Peritoneal dissemination is one of the main causes of death in cancer patients. Pathophysiology of metastasis has been well investigated, but the mechanism of diffuse spread of tumor colonies in the peritoneal cavity is not fully understood. CD9 is a member of tetraspanin and its down-regulation is known to be involved in poor prognosis. To investigate the significance of the down-regulation of CD9, HTOA, an ovarian carcinoma cell line that highly expressed CD9, was transiently transfected with small interfering RNA (siRNA) against CD9, and CD9-negative cells (HTOA(CD9-)) were purified. HTOA(CD9-) showed altered adhesion patterns on Matrigel, collagen, fibronectin, and laminin compared with those of control siRNA-transfected HTOA (control-HTOA). Flow cytometry and fluorescence cytostainings revealed that the expression levels of integrins beta1, alpha2, alpha3beta1, alpha5, and alpha6 were lower in HTOA(CD9-) than those of control-HTOA. HTOA(CD9-) showed altered expression of junctional and cytoskeletal molecules. By time-lapse video microscopy, control-HTOA showed solid adhesion to extracellular matrix and formed cobblestone pattern, whereas HTOA(CD9-) showed weaker adhesion and were distributed as diffuse spots. To examine whether the expression level of CD9 change during tumor dissemination, HTOA-P, a highly disseminative subclone of HTOA, was established. HTOA-P showed distinctive down-regulation of CD9 at mRNA and protein levels, and showed similar morphologic alteration as HTOA(CD9-) did. These findings indicate that the down-regulation of CD9 may be an acquired event in the process of tumor dissemination. Down-regulated CD9 may attenuate the expression of several integrins and rearrange junctional and cytoskeletal molecules that might contribute to dissemination of ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805258     DOI: 10.1158/0008-5472.CAN-04-3123

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

Review 2.  Tetraspanins: push and pull in suppressing and promoting metastasis.

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

3.  Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Authors:  Haydee Lara; Yuhua Wang; Adriana S Beltran; Karla Juárez-Moreno; Xinni Yuan; Sumie Kato; Andrea V Leisewitz; Mauricio Cuello Fredes; Alexei F Licea; Denise C Connolly; Leaf Huang; Pilar Blancafort
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

4.  Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma.

Authors:  Li Chen; Daiyue Yuan; Gui-lan Wang; You Wang; Yuan-Yuan Wu; Jianwei Zhu
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

5.  The tetraspanin superfamily member NET-6 is a new tumor suppressor gene.

Authors:  Huayi Huang; Khalid Sossey-Alaoui; Sarah H Beachy; Joseph Geradts
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

Review 6.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 7.  Targeting of tetraspanin proteins--potential benefits and strategies.

Authors:  Martin E Hemler
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

8.  MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells.

Authors:  Zheng Wu; Zhiyong Wu; Jun Li; Xiaomei Yang; Yahui Wang; Yi Yu; Jun Ye; Congjian Xu; Wenxin Qin; Zhigang Zhang
Journal:  Tumour Biol       Date:  2012-05-19

9.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18

Review 10.  Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.

Authors:  Christopher S Stipp
Journal:  Expert Rev Mol Med       Date:  2010-01-18       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.